What this means
This is a trial that is still recruiting people, so no results have been posted yet. It will test whether NMN tablets affect immune aging, blood sugar, and fat levels.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 50–70
- Where
- 1 site
The science
- Registered title
- The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
- Trial ID
- NCT06907329 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Immunosenescence, Metabolism
- What is tested
- NMN, Placebo
- Sponsor
- Qing Su
- Ages
- 50 Years to 70 Years
- Dates
- First posted Apr 2, 2025 · updated Jul 8, 2025
Registry summary
The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.
Sites (1)
- Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China